Enveric Biosciences(ENVB)
4.20+0.25+6.33%
行情数据延迟15分钟
- 最新
- 推荐
暂无内容公司概况
公司名称Enveric Biosciences所属市场NASDAQ成立日期- -员工人数- -办公地址- -邮政编码- -联系电话- -联系传真- -公司概况Enveric Biosciences, Inc.于1994年2月根据特拉华州法律成立。Enveric Biosciences是一家生物技术公司，致力于开发新一代小分子神经可塑性疗法，以满足精神和神经系统疾病领域尚未满足的医疗需求。该公司利用其独特的药物发现平台和不断增长的专利保护化学结构库，推进一系列旨在促进神经可塑性且不产生致幻作用的新型化合物的研发。其主要候选药物EB-003是一种旨在选择性地与5-HT2A和5-HT1B受体结合的化合物，有望提供快速起效、持久的抗抑郁和抗焦虑作用，适用于门诊治疗。- 04-18Form 8-K - Current report重要事件披露Form 8-K - Current report
- 03-27Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]年度报告Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
- 03-27Form 8-K - Current report重要事件披露Form 8-K - Current report
- 02-10Form S-1 - General form for registration of securities under the Securities Act of 1933招股说明书Form S-1 - General form for registration of securities under the Securities Act of 1933
- 02-06Form 8-K - Current report重要事件披露Form 8-K - Current report
- 01-28Form 8-K - Current report重要事件披露Form 8-K - Current report
- 01-09Form 8-K - Current report重要事件披露Form 8-K - Current report
- 2025-12-22Form S-8 - Securities to be offered to employees in employee benefit plans员工持股计划Form S-8 - Securities to be offered to employees in employee benefit plans
- 2025-12-12Form 8-K - Current report重要事件披露Form 8-K - Current report
- 2025-12-11Form 8-K - Current report重要事件披露Form 8-K - Current report
- 2025-12-08Form CORRESP - CorrespondenceSEC问询函Form CORRESP - Correspondence
- 2025-11-14Form 8-K - Current report重要事件披露Form 8-K - Current report
- 2025-11-14Form 10-Q - Quarterly report [Sections 13 or 15(d)]季度报告Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2025-11-14Form 8-K - Current report重要事件披露Form 8-K - Current report
- 2025-10-23Form 8-K - Current report重要事件披露Form 8-K - Current report
- 分时
- 5日
- 日
- 周
- 月
数据加载中...
最高
4.60
今开
3.74
量比
0.05
最低
3.70
昨收
3.95
换手率
26.25%